SPTBN5

Across TCGA pan-cancer cohorts, SPTBN5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPTBN5 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SPTBN5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPTBN5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where SPTBN5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.657	1.000	.010	14	view →
CCRCC	DFS	Median	All	0.914	0.607	.005	9	view →
LSCC	OS	Median	All	0.669	1.000	.008	7	view →
UCEC	DFS	Median	All	0.646	1.000	.008	6	view →
GBM	OS	Median	All	0.531	0.274	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPTBN5–LUAD (DFS)

Open the LUAD breakdown →